## PATENT APPLICATION DOCKET NO.: 0725.1059-001

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants	: David M. Knipe, Travis J. Taylor, Elizabeth E. McNamee	10971 U.S.
Continuation	on Application of	10/0
Арр	plication No.: 09/127,227	70
File	ed: July 31, 1998	
For:	Replication-Competent Virus Expressing A Detectable Fusion Protein	
	Date: 01/14/02 Express Mail Label No. ££93059887945	
	INFORMATION DISCLOSURE STATEMENT	
	Commissioner for Patents on, D.C. 20231	
*	mation Disclosure Statement is submitted:	
L 3	der 37 CFR 1.129(a), or t'Second submission after Final Rejection)	
(With stage	der 37 CFR 1.97(b), or hin any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, or a Request for Continued Examination).	e national n, including a
[ ] und	der 37 CFR 1.97(c) together with either:	
[ ]	a Statement under 37 CFR 1.97(e), as checked below, or	
[ ]	a \$180.00 fee under 37 CFR 1.17(p), or	

[ ] under 37 CFR 1.97(d) together with:

a Statement under 37 CFR 1.97(e), as checked below, and

(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)

a \$180.00 fee under 37 CFR 1.17(p), or

(Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)

[ ] under 37 CFR 1.97(i):

Applicant requests that the IDS and cited reference(s) be placed in the application filewrapper. (Filed after payment of issue fee)

10/050673

[ ]

[ ]

## Statement Under 37 CFR 1.97(e) Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. Statement Under 37 <u>CFR 1.704(d)</u> (Patent Term Adjustment) Applies to original applications (other than design) filed on or after May 29, 2000 Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement. [X] Enclosed herewith is form PTO-1449: Copies of the cited references are enclosed. [ ] Copies of cited references are enclosed except those entered in prior application, U.S. Application No. 09/127,227, to which priority under 35 U.S.C. 120 is claimed. The [X]earlier application contains copies of the cited references. The listed references were cited in the enclosed International Search Report in a counterpart foreign application. The "concise explanation" requirement (non-English references) for reference(s) [ 1 under 37 CFR 1.98(a)(3) is satisfied by: the explanation provided on the attached sheet. the explanation provided in the Specification.

submission of the enclosed International Search Report.

the enclosed English language abstract.

submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action.

lixaminer's Initials					
		U.\$	S. Patent Application No. [	], by [inventor(s)], filed [	], Docket No.: [ ]
		U.S	S. Patent Application No. [	], by [inventor(s)], filed [	], Docket No.: [ ]
		U.\$	S. Patent Application No. [	], by [inventor(s)], filed [	], Docket No.: [ ]
		Ex	aminer	Date	_
	[ ]	A	copy of each above-cited app	blication, including the curre	ent claims, is enclosed.
	[ ]	tho	copy of each above-cited appose entered in prior application. U.S.C. 120 is claimed.	olication, including the curre on, U.S. Application No. [	ent claims, is enclosed, except ], to which priority under
The E	xami nces	ner is r were co	requested to return a copy of onsidered with the next office	the above list of pending ap	plications indicating which
It is re	ques	ted tha	t the information disclosed h	erein be made of record in t	his application.
Metho	od of	payme	nt:		
[ ]	A c	theck for the fee noted above is enclosed, or the fee has been included in the check with the ompanying Reply. A copy of this Statement is enclosed.			
[ ]	Ple enc	ase cha losed.	arge Deposit Account 08-038	30 in the amount of \$[	]. A copy of this Statement is
[X]	Ple	ase cha	arge any deficiency in fees ar	nd credit any overpayment to	Deposit Account 08-0380.
			I	Respectfully submitted,	
			I	HAMILTON, BROOK, SMI	TH & REYNOLDS, P.C.
			Ī	3v Antonette &	Levelaur

Antoinette G. Giugliano Registration No.: 42,582 Telephone: (978) 341-0036 Facsimile: (978) 341-0136

Concord, MA 01742-9133 Dated: 11567

INFORMATION DISCLOSURE CITATION

PTO 1449 REPRODUCED

EXAMINER

0725.1059-001

APPLICATION NO.

APPLICANT

INFORMATION DISCLOSURE CITATION IN AN APPLICATION			David M. Knipe et al.				
	January 15, 2002			FILING DATE January 16, 2002	GROUP		10/
			U.S.	PATENT DOCUMENTS			
EXAM INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
_	AA	4,859,587	22-AUG-89	Roizman	435	68	
	АВ	5,288,641	22-FEB-94	Roizman	435	320.1	
	AC	5,328,688	12-JUL-94	Roizman	424	205.1	
	AD	5,658,724	19-AUG-97	DeLuca	435	5	
	AE	5,665,362	09-SEP-97	Inglis et al.	435	5	
	AF						
	AG					<u> </u>	
			FOREIG	N PATENT DOCUMENTS		<del></del>	
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	AL	0277773	28-JAN-88	EPO			
	AM	WO89/09271	05-OCT-89	PCT			
	AN	0453242	16-APR-91	EPO			
	AO	WO92/05263	02-APR-92	PCT			
	AP	WO94/03207	17-FEB-94	PCT			
	AQ	WO94/21807	29-SEP-94	PCT			
	AL2	WO94/03595	17-FEB-94	PCT			
	AM2	WO94/01573	20-JAN-94	PCT			
		OTHER DOCUMENTS	(Including Au	thor, Title, Date, Pertin	ent Pages,	Etc.)	
	AR	Shih, MF. et al., "Expression of hepatitis B virus $S$ gene by herpes simplex virus type 1 vectors carrying $\alpha$ - and $\beta$ -regulated gene chimeras," <i>Proc. Natl. Acad. Sci. USA</i> , 81:5867-5870 (1984).					
	AS	Nguyen, L.H. et al., "Replication-Defective Mutants of Herpes Simplex Virus (HSV) Induce Cellular Immunity and Protect against Lethal HSV Infection," J. Virol., 66(12):7067-7072 (1992).					
	АТ	Gao, M. and Knipe, D.M., "Genetic Evidence for Multiple Nuclear Functions of the Herpes Simplex Virus ICP8 DNA-Binding Protein," $J$ . $Virol.\ 63(12):5258-5267\ (1989)$ .					

DATE CONSIDERED

PTC 1449 REPRODUCED		Capuac	ATTORNEY DOCKET NO. 0725.1059-001	APPLICATION NO.	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION		IN AN APPLICATION	APPLICANT David M. Knipe et al.		
January 15, 2002			FILING DATE January 16, 2002	GROUP	
		OTHER DOCUMENTS (Including Au	thor, Title, Date, Pertinent	Pages, Etc.)	
	AU	Cunningham, C. et al., "The UL13 virion protein of herpes simplex virus type 1 is phosphorylated by a novel. virus-induced protein kinase," J. Gen. Virol. 73:303-311 (1992).			
	AV	Ali, M.A. et al., "Enhanced malignant transformation induced by expression of a distinct protein domain of ribonucleotide reductase large subunit from herpes simplex virus type 2," Proc. Natl. Acad. Sci. USA, 88:8257-8261 (1991).			
	AW	Rice, S.A. and Knipe, D.M., "Genetic Evidence for Two Distinct Transactivation Functions of the Herpes Simplex Virus $\alpha$ Protein ICP27," J. Virol., 64:1704-1715 (1990).			
	AX	Rice, S.A. et al., "Herpes Simplex Virus Alpha Protein ICP27 Possesses Separable Positive and Negative Regulatory Activities," J. Virol., 63:3399-3407 (1989).			
	AY	Quinn, J.P. and McGeoch, D.J., "DNA sequence of the region in the genome of herpes simplex virus type 1 containing the genes for DNA polymerase and the major DNA binding protein," Nucl. Acids Res., 13(22):8143-8163 (1985).			
	AZ	Sacks, W.R. et al., "Herpes Simplex Virus Type 1 ICP27 is an Essential Regulatory Protein," <i>J. Virol.</i> 55(3):796-805 (1985).			
	AR2	Galloway, D.A. et al., "Small fragments of herpesvirus DNA with transforming activity contain insertion sequence-like structures, "Proc. Natl. Acad Sci. USA, 81:4736-4740 (1984).			
	AS2	Weller, S.K. et al., "Genetic Analysis of Temperature-Sensitive Mutants Which Define the Gene for the Major Herpes Simplex Virus Type 1 DNA-Binding Protein," J. Virol., 45(1):354-366 (1983).			
	AT2	Farrell, H. et al., "Vaccine potential of a herpes simples virus mutant lacking an essential glycoprotein," Abstract, 17th International Herpesvirus Workshop, Edinburgh, Scotland, Page 378 (August 1-7, 1992).			
	AU2	McLean, L. et al., "Protective vaccination with a gH-deleted HSV-1 virus," 18th International Herpesvirus Workshop, Pittsburgh, PA, page C-71 (July 25-30, 1993).			
	AV2	DeLuca, N.A. et al., "Isolation and Characterization of Deletion Mutants of Herpes Simplex Virus Type 1 in the Gene Encoding Immediate-Early Regulatory Protein ICP4," J. Virol., 56(2):558-570 (1985).			
	AW2	Jayaraman, S. et al., "Exacerbation of Murine Herpes Simplex Virus-Mediated Stromal Keratitis by Th2 Type T Cells," J. Immunol., 151(10):5777-5789 (1993).			
	AX2	Marchetti, M.E. et al., "A Temperature-Sensitive Mutation in a Herpes Simplex Virus Type 1 Gene Required for Viral DNA Synthesis Maps to Coordinates 0.609 through 0.614 in U <sub>L</sub> ," J. Virol., 62(3):715-721 (1988)			

DATE CONSIDERED

EXAMINER

PTO 1449 REPRODUCED			ATTORNEY DOCKET NO. 0725.1059-001	APPLICATION NO.		
INFORMATION DISCLOSURE CITATION IN AN APPLICATION			APPLICANT David M. Kline et al.			
January 15, 2002		January 15, 2002	FILING DATE January 16, 2002	GROUP		
		OTHER DOCUMENTS (Including Au	thor, Title, Date, Pertinen	t Pages, Etc.)		
	AY2	Ligas, M.W. and Johnson, D.C., "A Herpes Simplex Virus Mutant in which Glycoprotein D Sequences are Replaced by $\beta$ -Galactosidase Sequences Binds to but is Unable to Penetrate into Cells," <i>J. Virol.</i> , 62(5):1486-1494 (1988).				
	AZ2	Farrell, H.E. et al., "Vaccine Potential of a Herpes Simplex Virus Type 1 Mutant with an Essential Glycoprotein Deleted," J. of Virol. 68(2):927-932 (1994).				
	AR3	Morrison, L.A. and Knipe, D.M., "Immunization with Replication- Defective Mutants of Herpes Simplex Virus Type 1: Sites of Immune Intervention in Pathogenesis of Challenge Virus Infection," <i>J. Virol.</i> 68:689-696 (1994).				
	AS3	Nguyen, L. et al., "Mechanism of Virus-Induced Ig subclass Shifts," $J.$ Immunol. 152:478-484 (1994).				
	AT3	Fields, B.N. <i>et al</i> ., "Field's Virology," Lippincot-Raven Publishers, Philadelphia, PA, Chapters 72 (1996).				
	AU3	Sambrook, et al., "Molecular Cloning: A Laboratory Manual," 2nd ED., Chapter 17 (1989).				
	AV3	Cruz, et al., PNAS, 93: 6286-6290 (1996).				
	EWA	Gao, et al., Journal of Virology, 67: 876-885 (1993).				
	AX3	Stauber, et al., Virology, 213: 439-449 (1995).				
	AY3	Phelan, et al., Nat. Biotechnol., 16(5): 440-443 (1998).				
	AZ3	Loimas, et al., Biotechniques, 24(4): 614-618 (1998).				
	AR4	Gerdes, et al., FEBS letters, 389: 44-47 (1996).				
	AS4	Lee, et al., BBRC, 233: 288-292 (1997).				
	AT4	Brideau, et al., Journal of Virology , 72(6): 4560-4570 (1998).				
	AU4	Jons, et al., Journal of	Virological Methods, 66	: 283-292 (1997).		
	AV4	Desai, et al., Journal of Virology, 72(9): 7563-7578 (1998).				

DATE CONSIDERED

EXAMINER